Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > Hold the line on ARCH

<< Previous

Bullboard Posts

Next >>

Comment by stocksarefunon Dec 03, 2021 3:01pm

94 Views

Post# 34196246

RE:Hold the line on ARCH

My only issue is a serious lack of demand from new investors. Uplisting to access new pools of investors is fine, but with it also comes an insane amount of trickery from the US funds who want cheap shares as well, no?

<100k shares a day traded, with such amazing news, is crazy to me. Even considering where we were 3 months ago.

We should be getting at least a little bit more interest from canadian retail, canadian institutions, AND US retail who closely follow pharma/biotech sectors.

<< Previous

Bullboard Posts

Next >>

Geologica Resource: Polymetallic upside at a depressed price